MedPlus Health Services (MEDPLUS) Fundamentals 2026 — P/E 39.4x, Revenue Analysis | SniperIQ
MedPlus Health Services (MEDPLUS) is a India-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₹8,309 Crore, trading at ₹695.05 on the BSE. This SniperIQ fundamentals page covers MedPlus Health Services's valuation (P/E 39.4x, P/B 4.2x), profitability (net margin 2.9%), revenue (₹6,892 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MedPlus Health Services's market cap?
MedPlus Health Services (MEDPLUS) has a market capitalization of approximately ₹8,309 Crore, trading at ₹695.05 on the BSE. Market cap moves with the live share price.
What is MedPlus Health Services's P/E ratio?
MedPlus Health Services's trailing twelve-month P/E ratio is 39.4x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MedPlus Health Services?
MedPlus Health Services runs a net profit margin of 2.9%, a gross margin of 8.9%, and an operating margin of 4.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MedPlus Health Services generate?
MedPlus Health Services reported revenue of ₹6,892 Crore for fiscal year 2026, with net income of ₹220 Crore and earnings per share (EPS) of 18.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MedPlus Health Services pay a dividend?
MedPlus Health Services does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MedPlus Health Services financially healthy?
MedPlus Health Services carries a debt-to-equity ratio of 0.72x and a current ratio of 3.00x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MedPlus Health Services a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MedPlus Health Services (MEDPLUS) the key facts are: market cap ₹8,309 Crore, P/E 39.4x, revenue ₹6,892 Crore, 52-week range 653.8-1020.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MedPlus Health Services's full fundamentals live
Get MedPlus Health Services's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.